@article{ref1,
title="Evaluation of the efficacy of pimavanserin in the treatment of agitation and aggression in patients with Alzheimer's disease psychosis: a post hoc analysis",
journal="International journal of geriatric psychiatry",
year="2020",
author="Ballard, Clive G. and Coate, Bruce and Abler, Victor and Stankovic, Serge and Foff, Erin",
volume="ePub",
number="ePub",
pages="ePub-ePub",
abstract="OBJECTIVES: Patients with Alzheimer's disease psychosis (ADP) commonly experience concomitant agitation and aggression. We investigated whether a reduction in ADP following pimavanserin treatment conferred a reduction in associated agitation and aggression.   METHODS: ACP-103-019 was a 12-week, randomized, double-blind, placebo-controlled study that evaluated the efficacy of pimavanserin (34 mg) in reducing psychotic symptoms in patients with ADP. The primary endpoint was change from baseline in Neuropsychiatric Inventory-Nursing Home Version-Psychosis Score (NPI-NH-PS) at week six. A post hoc analysis examined whether there was a greater reduction in agitation and aggression (NPI-NH domain C [agitation/aggression] and Cohen-Mansfield Agitation Inventory-Short Form [CMAI-SF]) in pimavanserin-treated patients who experienced a reduction of hallucinations and delusions (psychosis responders defined as ≥50% reduction from baseline in NPI-NH-PS, week six) when compared with those who did not (nonresponders).   RESULTS: Pimavanserin-treated patients with ≥50% response in psychotic symptoms (n = 44) showed a greater improvement in agitation and aggression symptoms on the NPI-NH domain C (week six, least squares mean [LSM] difference = -3.64, t = -4.69, P < 0.0001) and the CMAI-SF (week six, LSM difference = -3.71, t = -2.01, P = 0.0483) than nonresponders (n = 32). Differences between psychosis responders and nonresponders were also observed in patients with more severe agitation and aggression at baseline on the NPI-NH domain C (responders, n = 26; nonresponders, n = 13; week six, LSM difference = -3.03, t = -2.44, P = 0.019).   CONCLUSIONS: Patients with ADP who show improvement in psychotic symptoms following pimavanserin treatment also experience an improvement in concomitant agitation and aggression. This article is protected by copyright. All rights reserved.<p /> <p>Language: en</p>",
language="en",
issn="0885-6230",
doi="10.1002/gps.5381",
url="http://dx.doi.org/10.1002/gps.5381"
}